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Background: Rural residents face numerous barriers to healthcare access and studies suggest poorer health
outcomes for rural patients. Therefore we undertook a systematic review to determine if cardiovascular medication
utilization and adherence patterns differ for rural versus urban patients.
Methods: A comprehensive search of major electronic datasets was undertaken for controlled clinical trials and
observational studies comparing utilization or adherence to cardiovascular medications in rural versus urban adults
with cardiovascular disease or diabetes. Two reviewers independently identified citations, extracted data, and
evaluated quality using the STROBE checklist. Risk estimates were abstracted and pooled where appropriate using
random effects models. Methods and reporting were in accordance with MOOSE guidelines.
Results: Fifty-one studies were included of fair to good quality (median STROBE score 17.5). Although pooled
unadjusted analyses suggested that patients in rural areas were less likely to receive evidence-based cardiovascular
medications (23 studies, OR 0.88, 95% CI 0.79, 0.98), pooled data from 21 studies adjusted for potential confounders
indicated no rural–urban differences (adjusted OR 1.02, 95% CI 0.91, 1.13). The high heterogeneity observed (I2 = 97%)
was partially explained by treatment setting (hospital, ambulatory care, or community-based sample), age, and disease.
Adherence did not differ between urban versus rural patients (3 studies, OR 0.94, 95% CI 0.39, 2.27, I2 = 91%).
Conclusions: We found no consistent differences in rates of cardiovascular medication utilization or adherence among
adults with cardiovascular disease or diabetes living in rural versus urban settings. Higher quality evidence is needed to
determine if differences truly exist between urban and rural patients in the use of, and adherence to, evidence-based
medications.
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Rural and urban communities have distinct characteristics
in terms of demographics, social, and physical environ-
ments, and may vary in access to healthcare facilities and
services. Rural residents tend to be older and are more
likely to be obese, have less education, and lower income
than urban residents [1-6]. Rural populations also have a
higher prevalence of chronic conditions such as diabetes
and heart disease [1,7-9]. Some studies have shown worse* Correspondence: deurich@ualberta.ca
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unless otherwise stated.health outcomes among rural populations, including a
higher risk of cardiovascular-related morbidity and mor-
tality compared to urban populations [3,4,10-13]. For
example, in Canada, mortality from circulatory diseases is
higher in rural than urban communities, as is the risk
of heart failure-related mortality, hospitalization and
emergency department visits [4,10,11]. Similarly, in the
UK a higher risk of in-hospital death due to ischemic
heart disease has been observed among rural residents
[12], and in Australia, mortality due to six major chronic
diseases consistently increased in areas that were in-
creasingly remote [13]. Collectively, these characteristics
suggest increased healthcare needs for those living in rural
communities.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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accessing healthcare including transportation difficulties
and distance to care, social isolation, financial con-
straints, limited health care facilities (hospitals and phar-
macies), physician shortages, and lack of access to
specialist care [14-19]. Indeed, in the US, rural areas
contain 19% of the population but only 11% of the phys-
ician workforce [15], and the ratio of specialists per
population consistently declines as locations become
smaller and more remote [15,17]. The lack of access to
primary care physicians, specialists, or health care facilities
has been postulated to result in decreased prescribing of
evidence based medications. However, a previous system-
atic review found no clear rural–urban difference in the
prevalence or intensity of prescription drug use in older
adults – although that review included a wide variety of
health conditions and medications [20]. It is possible that
important differences may exist for certain disease states
or medication conditions. As a result, we conducted a
systematic review that evaluated whether cardiovascular-
related medication utilization and adherence patterns
differ for rural versus urban adults with cardiovascular
disease or diabetes. These two disease states were selected
as they affect a large number of patients, are associated
with high morbidity and mortality, often require multiple
medications to manage, and outcomes are known to be
different between rural and urban patients [21].
Methods
Inclusion and exclusion criteria
Controlled clinical trials or observational studies were
included if they enrolled adults with established cardio-
vascular disease (atrial fibrillation, hypertension, heart
failure, coronary artery disease) or diabetes, and reported
cardiovascular medication use or adherence patterns for pa-
tients living in rural versus urban communities. Medications
of interest included acetylsalicylic acid (ASA), antithrom-
botic, anticoagulant, antihypertensive (including angiotensin
converting enzyme inhibitors (ACEI) and angiotensin recep-
tor blockers (ARB)), or lipid lowering agents. The research
question, inclusion and exclusion criteria, and review
methods were outlined in a protocol developed a priori ac-
cording to the PRISMA guidelines [22].
Since the definition of rural and urban varied substan-
tially between studies, we a priori defined populations
described as urban, city dwelling, or metropolitan in the
primary publication as urban. Conversely, rural descrip-
tors included town, village, country dwelling, non-
metropolitan or remote communities. Any definition of
adherence or persistence used in primary studies was ac-
cepted. Only full text, peer reviewed articles, were in-
cluded. Studies evaluating the use of medications for
acute management, such as during hospitalization, were
excluded, as were studies conducted in developingcountries where management approaches may be sub-
stantially different. The populations of interest were those
with established cardiovascular disease or diabetes, in whom
several evidence-based medications are recommended for
use. Two researchers (GKM, DLW) independently screened
all studies and extracted all data using pre-defined forms and
definitions, and disagreements were resolved through discus-
sion, or by a third researcher (DTE).
Literature search strategy
A comprehensive search strategy implemented by a re-
search librarian was done in April 2012 in the following
electronic databases: MEDLINE®, PubMed, Embase,
International Pharmaceutical Abstracts, CINAHL, and
Web of Science® and reference lists of included articles
were also manually searched. Previously identified in-
cluded studies were searched in Scopus to gather add-
itional subject headings. No language, study design or
date restrictions were applied. The MEDLINE® search
strategy is listed in (Additional file 1: Table S1).
Data extraction and quality assessment
Studies were evaluated for bias, and the STROBE checklist
was used to assess the quality of reporting [23]. Study au-
thors were contacted for missing information on rural–urban
comparisons, and in two cases additional data were provided
(unpublished data V. Maio 2012, I. Carey 2011). Both un-
adjusted and adjusted data were abstracted or calculated
where possible [24]. If more than one adjusted analysis was
reported, the analysis that adjusted for the most confounders
was extracted, and medication use data for patients without
contraindications to treatment were preferred over popula-
tions that may have included patients who were not eligible
for a specific therapy. Where possible, studies reporting mul-
tiple rural or urban populations were combined.
Data analysis methods
To summarize the effects of rural and urban location on
medication utilization or adherence both unadjusted and
adjusted pooled effects were calculated. As we expected
heterogeneity between studies, we pooled effect esti-
mates using a random effects model with inverse vari-
ance weighting and Review Manager 5.1 software [25].
Heterogeneity was assessed using the I2 statistic with an
I2 statistic >50% being considered as moderate hetero-
geneity. There was no a priori degree of heterogeneity
that precluded pooling. For studies reporting multiple
outcomes within the same cohort [e.g., % receiving beta-
blockers (BB) and % receiving an ACEI], a pooled esti-
mate of the odds of treatment were calculated using
methods recommended by Borgenstein et al. [26] that
accounts for the fact that patients within each outcome
are not mutually exclusive (i.e., a patient may have re-
ceived both a BB and an ACEI). Since the correlation of
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of 0.5 with sensitivity analyses using 0.25, 0.75 or 1 and
found there was little impact on the results. Subgroup
analyses were further conducted to explore the robust-
ness of our results and potential sources of heterogen-
eity. Studies reporting data not suitable for meta-analysis
(e.g. outcomes other than OR, or with missing data)
were summarized narratively. Publication bias was
assessed using funnel plots and Egger’s test.
Results
A total of 11092 citations were identified in the literature
search and 51 unique studies (described in 52 publica-
tions), met the inclusion criteria (Figure 1) [2,8,9,27-75].
Fifteen studies were cohort studies and 36 were cross sec-
tional or repeat cross sectional studies (Additional file 1:
Table S2). The included studies were published over a
21-year time span (1990 to 2011) and had quality scores
based on the STROBE checklist that ranged from 8.5 to
21 (median 17.5) out of a total of 22 possible items (0.5
points given for partial reporting). Two reports providedInitial search Aug 2010 n=8145
Update April 2012 n=2938
Hand search n=9
Total identified citations n=11092
Titles and abstracts reviewed: first round (n=11092)
Excluded: 
Duplicates n=220
Not relevant population n=4649
No medication use data n=1445
Non-human or cellular studies n=533
Not relevant to research question =1295
Review articles, letters, abstracts, uncontrolled studies n=1650
Titles and abstracts reviewed: second round (n=1300)
Excluded:
Duplicates n=3
Not relevant population n=397
No medication use data n=47
Review articles, letters, abstracts, uncontrolled studies n=32
Other n=58
Complete articles reviewed (n=763)
Excluded:
No rural urban comparison n=520
No cardiovascular medication use data n=32
Wrong population n=58
Wrong study design n=36
Abstract n=59
Duplicate n=5
Data included in another publication n=1
Articles included for review n=52 (51 unique studies)
Studies included in meta-analyses: 36
Figure 1 Flow chart of systematic search.data on the same study [44,48], and six studies included
data for more than one patient cohort [43,49,54,66,71,72].
Thus, 58 patient populations (or cohorts) were included in
our study. Two studies were in a language other than
English and were translated using on-line resources and
local expertise [37,70]. There was good agreement between
reviewers on study selection (kappa 0.82, 95% confidence
interval [CI] 0.75 to 0.90).
Patients were selected from a hospital setting in 12 stud-
ies, from ambulatory care practices in 17 studies, and in 22
studies, patients were selected from population-based or
community-dwelling samples. Exploring rural–urban dif-
ferences was the primary objective of 18 studies (35%)
[2,27,28,30,31,35,36,39,43,44,49,51,54,59,68,69,71,73]. Seven
studies reported medication adherence (the proportion of
doses taken as prescribed over a specific time period) or
persistence (the length of continuous treatment) [76], and
47 reported outcomes related to medication utilization.
Among the studies, there were substantial variations in
how medication utilization or adherence to medications
was assessed. Overall, 16 studies included patient self-
report, 31 studies included data from medical records or
registries, and 5 studies were conducted using administra-
tive databases. Nineteen studies reported crude utilization
or adherence outcome data only [8,28,35-37,39,40,50,51,
53,54,63,64,67,68,71,73-75].
Included studies varied in their characteristics (Additional
file 1: Table S2). Studies ranged in sample size from 32 to
approximately one million and were conducted in a range
of areas including the US (30 studies), Europe (14), Canada
(5) and Australia (2). Patient populations included those
with acute myocardial infarction or coronary artery disease
(18 studies), hypertension (16), diabetes (8), chronic heart
failure (6), atrial fibrillation (5), or mixed cardiovascular dis-
ease populations (5). The average age of study participants
ranged from 42 to 80 years, and 28% to 63% were female.
Medication utilization
Forty seven (92%) studies [2,8,9,27-36,38-47,49,51-69,
71-73,75] evaluated cardiovascular medication utilization
with 20 (39%) studies specifically evaluating utilization
of ASA or other anti-thrombotic agents, 34 (67%) evalu-
ating antihypertensive use, and 11 (22%) evaluating the
use of lipid lowering agents (Additional file 1: Table S3).
Substantial variation in the use of cardiovascular medi-
cations was observed between studies and between rural
versus urban sub-populations within each study. Indeed,
the absolute difference in the utilization of cardiovas-
cular medications ranged from −46% to +4% in rural
versus urban patients for ASA or other anti-thrombotic
drugs, −37% to +25% for antihypertensive drugs, and −45%
to +8% for lipid lowering agents. Of the 47 studies that
evaluated cardiovascular medication use, sufficient data
for pooling were available in 34 studies (39 separate
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[43,66,72] and three cohorts in one study [71]). In the un-
adjusted pooled analyses (23 studies) [27-29,35,36,38,39,
41,43,44,46,47,51,53,55-58,64,68,71,73,75], patients in rural
areas with cardiovascular disease or diabetes were less
likely to receive evidence-based cardiovascular drug
therapy compared to urban residents (pooled unadjusted
OR 0.88, 95% CI 0.79, 0.98, p = 0.02; I2 = 97%) (Table 1).Table 1 Meta-analysis of medication utilization and adherenc
Analysis N cohorts*
Cardiovascular medication utilization
Overall - unadjusted 26
Overall - adjusted 23
Subgroup analysis – adjusted
Setting
Community or population-based 8
Hospital 6
Ambulatory care practice 9
Drug class
Antithrombotic or anticoagulant 9
Antihypertensive 16






















Overall - unadjusted 4
*Data from 23 and 21 studies were included in the unadjusted and adjusted analys
for more than one cohort. CI = confidence interval; NA = not applicable; OR = odds rHowever, among the 21 studies that adjusted for potential
confounders [9,27,29,34,38,41-45,47,52,55,56,58,60-62,66,
69,72] pooled analysis indicated no statistically significant
difference between rural and urban patients in the use of
cardiovascular medications (pooled adjusted OR 1.02, 95%
CI 0.91 to 1.13, p = 0.77, I2 = 97%) (Figure 2). In both ana-
lyses there was substantial heterogeneity between studies.





0.88 (0.79, 0.98) 97 NA
1.02 (0.91, 1.13) 97 NA
1.15 (1.06, 1.25) 71 P < 0.0001
0.87 (0.83, 0.92) 34
1.02 (0.85, 1.24) 78
1.00 (0.88, 1.14) 88 P = 0.62
1.03 (0.90, 1.17) 92
0.94 (0.83, 1.07) 37
0.83 (0.59, 1.16) 67 P = 0.0001
0.95 (0.88, 1.03) 67
1.07 (0.87, 1.33) 79
1.21 (1.12, 1.31) 76
1.15 (1.04, 1.26) 80 P = 0.005
0.98 (0.88, 1.08) 70
0.89 (0.77, 1.02) 64
1.01 (0.92, 1.10) 87 P = 0.67
1.05 (0.88, 1.26) 88
1.06 (0.91, 1.22) 76 P = 0.66
1.01 (0.88, 1.15) 98
1.17 (0.97, 1.41) 87 P = 0.19
0.97 (0.87, 1.08) 86





0.94 (0.39, 2.27) 91 NA
es, respectively: Ellis [43], Rice [66], Wan [71], and Williams [72] provided data
atio.
Figure 2 Use of cardiovascular drugs by rural versus urban patients, stratified by study setting (adjusted analysis).
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undertaken, similar results were observed and these fac-
tors only partially explained some of the variation between
studies (Table 1; Figures 2 and 3). Moreover, when studies
were categorized according to how the outcome was
assessed (patient self-report, medical chart review, or
administrative data), similar results were observed (Table 1).
Additional analyses by study quality, for countries with
universal health care systems, and for specific drugs,
such as ACEI/ARB, also found similar findings (Additional
file 1: Table S4). Among studies reporting data not suitable
for meta-analysis, the findings were also consistent in that
there was no clear trend towards a reduction or increase
in cardiovascular medication utilization between rural and
urban patients [2,8,30-33,40,49,54,59,63,65,67].
Publication bias was assessed by visually examining fun-
nel plots and no obvious asymmetry was noted (Egger’s
p value = 0.98).
Medication adherence or persistence
Six (12%) studies [29,37,46,70,73,74] evaluated cardio-
vascular medication adherence and two (4%) studies
[46,50] evaluated medication persistence. Adherence was
measured as the percentage of doses taken [73], the pro-
portion of patients with a medication possession ratio≥0.8 [46], and was undefined in three studies [37,70,74].
Persistence was measured as the proportion of patients
remaining on the same [46,50] or any treatment [46] at
the end of the follow up. In five studies, the drugs evalu-
ated were antihypertensive agents, one study evaluated
heart failure medications [73], and one assessed ASA or
ACEI/ARB adherence [29].
Cardiovascular medication adherence or persistence
findings were inconsistent across studies (Additional file 1:
Table S3). The absolute difference in proportion adherent
or persistent with medications ranged from −41% to +8%
for rural versus urban patients. The odds of treatment
persistence were significantly higher in rural versus
urban patients in one report (adjusted OR 1.28, 95% CI
1.25, 1.32) [46], but was not statistically different in a
second study (OR 0.96, 95% CI 0.55, 1.67) [50], Medica-
tion adherence data from three studies (4 cohorts) were
pooled and showed no statistically significant difference
between rural and urban patients (unadjusted OR 0.94,
95% CI 0.39, 2.27, p = 0.89, I2 = 91%) Table 1 [29,37,70].
In two other reports with data not suitable for meta-
analysis, medication adherence was significantly higher
in one study (92% versus 83% of doses taken, p = 0.01)
[73], and significantly lower in the other (10% versus 17%
of patients compliant, p < 0.01) [74], for rural versus urban
Figure 3 Use of cardiovascular drugs by rural versus urban patients, stratified by disease (adjusted analysis).
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reporting treatment adherence adjusted for confounders
reported adherence to be significantly higher in rural
patients (OR medication possession ratio ≥0.8: antihy-
pertensive agents 1.2, 95% CI 1.1, 1.3; ASA 1.14, 95% CI
1.10, 1.18; ACEI/ARB 1.18 95% CI 1.14, 1.23) or rural
men (OR adherent 4.0, 95% CI 1.1, 13.9) [29,46,70].
Discussion
Our systematic review of the literature found that rural
patients were 12% less likely to receive cardiovascular
medications than urban patients in unadjusted analyses;
however, pooling of data adjusted for patient, practi-
tioner or other factors revealed no differences in the
proportions of rural and urban patients receiving therapy.
This suggests that differences in these characteristics
between rural and urban residents are largely respon-
sible for the discrepancies in medication use observed
and is consistent with previous studies showing import-
ant differences in the demographics, health behaviors,
and overall health of people living in rural and urban
areas [1,3,4,7]. In this review, many of the includedreports provided little data on the demographics or co-
morbidities of the rural and urban patient groups, which
hindered our ability to assess the similarity of these popu-
lations. As a result, it is difficult to draw conclusions from
those studies that reported only unadjusted rural–urban
comparisons.
When medication utilization data were pooled, substan-
tial between-study heterogeneity was observed (I2 = 97%).
Some of this variability could be explained by differ-
ences in the setting (hospital, ambulatory care practice
or community-based sample), age, and disease state.
While most studies adjusted for some clinical character-
istics, only some controlled for socioeconomic factors
that could also have impacted medication use. Indeed
only fourteen studies [27,32,34,42,43,45,47,52,57,58,61,
62,66,69] reported adjustment for health insurance and
previous studies have shown patients with a chronic
condition who lack medication insurance are less likely
to take medications or frequently skip doses due to cost
[52,66,77].
Similarly, we found no consistent relationship between
rural residence and cardiovascular medication adherence
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justed analysis suggested higher adherence and persistence
for rural residents, although there were few studies
reporting these outcomes. Rural–urban differences in
other health behaviors, such as smoking, exercise, and
consumption of fruits and vegetables have been reported
[4], and considering the link between adherence and posi-
tive health outcomes [78], further study is warranted.
Although we conducted an exhaustive search for litera-
ture and conducted our systematic review in accordance to
the highest reporting standards, our review is not without
limitations. Firstly, studies evaluating differences in urban
versus rural settings within subgroup analyses may not have
been easily identified. Second, as in any systematic review,
the findings are limited by the quality of the individual
studies. Potential limitations included reporting bias [32,
33,40,41,45,49,51,54,71,72], selection bias [9,35,54], lack
of generalizability [9,28,36,37,39,50,51,59,71,73,74], limited
sample size [28,36,37,39,50,64,73], no adjustment for
confounders [8,28,35-37,40,50,54,64,74,75], and poor re-
porting (STROBE score below the 25th percentile)
[8,28,36,37,40,44,50-52,54,59,64,70,71,74]. Third, we ac-
cepted a broad range of definitions for rural and urban
populations, which may have affected study results.
In 25 studies [8,28,34,36,37,40-43,45,46,50,52,53,55-60,
64-66,72,74] no clear definition of rural and urban
were provided and various definitions were used in the
remaining studies. It is possible some of the heterogen-
eity observed in our pooled analysis is related to these
differences in definitions, although subgroup analysis by
studies with defined and undefined rural populations
showed similar results. Fourth, between-study heterogen-
eity was high and not fully explained despite multiple sub-
group analyses by setting, drug class, disease, age, country,
publication year, and data source (self-report, administra-
tive or medical records). Moreover, clinical indications
and classification of disease may also have changed over
time increasing the heterogeneity between studies. Last,
our review only included adults with established cardio-
vascular disease as medication utilization for secondary
prevention was expected to be high within patients; thus,
improving the power to detect differences if differences
exist between rural and urban patients. Moreover, as
cardiovascular medications are widely prescribed medi-
cations in the general adult population, our results
would be expected to be highly generalizable.
Conclusions
In conclusion, we found no consistent relationship be-
tween rural versus urban residence and utilization of, or
adherence with evidence-based cardiovascular medica-
tions among adults with cardiovascular disease or dia-
betes. There was substantial between-study variation
that was only partially explained by the setting, age, anddisease. Higher quality evidence is needed to determine
if differences in cardiovascular medication utilization and
adherence between urban and rural patients truly exist.
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